Sight Sciences, Inc. (SGHT)Healthcare | Medical Devices | Menlo Park, United States | NasdaqGS
8.80 USD
+0.55
(6.667%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 8.80 |
Hot Take ↕ | Oct. 10, 2026, 11:27 a.m. EDT
The investment case for Sight Sciences is currently broken by a severe multi-year structural decline. Despite a recent guidance raise and positive gross margins, the stock has lost over 85% of its value over the last four years, with the most recent annual return being a sharp 42% drop. This trajectory confirms that the market views the current business quality as insufficient to sustain the current valuation, rendering any 'value' arguments moot. The company is burning cash with negative free cash flow and negative operating cash flow, and insiders have been selling shares, signaling a lack of confidence from those closest to the operations. While the recent price action shows a slight bounce off the lows, the fundamental reality of deteriorating equity value and persistent losses makes this a dangerous hold for capital preservation. There is no dividend to cushion the blow, and the statistical models offer no reliable short-term directional signal to counteract these glaring fundamental flaws. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.411022 |
| AutoARIMA | 0.413200 |
| AutoETS | 0.416641 |
| MSTL | 0.421998 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 2.40 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 79.355 |
| Revenue per Share | 1.559 |
| Market Cap | 484,774,336 |
| Forward P/E | -20.36 |
| Beta | 2.45 |
| Profit Margins | -35.69% |
| Website | https://www.sightsciences.com |
As of Oct. 10, 2026, 11:27 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume at deep strikes ($2.50) for the November expiration, suggesting a fear of a significant drop below current levels. Conversely, call activity is sparse and concentrated at lower strikes, while the February expiration shows some out-of-the-money call interest at $12.50, indicating a distant, speculative hope for a recovery rather than immediate bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3913043 |
| Address1 | 4,040 Campbell Avenue |
| Address2 | Suite 100 |
| All Time High | 42.57 |
| All Time Low | 1.04 |
| Ask | 10.91 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 364,760 |
| Average Daily Volume3 Month | 272,429 |
| Average Volume | 272,429 |
| Average Volume10Days | 364,760 |
| Beta | 2.446 |
| Bid | 6.46 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 0.967 |
| City | Menlo Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.8 |
| Current Ratio | 4.949 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 9.01 |
| Day Low | 8.53 |
| Debt To Equity | 79.355 |
| Display Name | Sight Sciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,960,000 |
| Earnings Call Timestamp Start | 1,785,960,000 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -19,264,000 |
| Ebitda Margins | -0.23105 |
| Enterprise To Ebitda | -23.204 |
| Enterprise To Revenue | 5.361 |
| Enterprise Value | 446,995,328 |
| Eps Current Year | -0.49264 |
| Eps Forward | -0.43215 |
| Eps Trailing Twelve Months | -0.55 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 352 4401 |
| Fifty Day Average | 8.3186 |
| Fifty Day Average Change | 0.4814005 |
| Fifty Day Average Change Percent | 0.057870377 |
| Fifty Two Week Change Percent | 139.13043 |
| Fifty Two Week High | 9.713 |
| Fifty Two Week High Change | -0.9130001 |
| Fifty Two Week High Change Percent | -0.09399775 |
| Fifty Two Week Low | 3.37 |
| Fifty Two Week Low Change | 5.4300003 |
| Fifty Two Week Low Change Percent | 1.6112761 |
| Fifty Two Week Range | 3.37 - 9.713 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,355,800,000 |
| Float Shares | 35,522,389 |
| Forward Eps | -0.43215 |
| Forward P E | -20.3633 |
| Free Cashflow | -8,611,250 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 186 |
| Fullday Change | 0.5500002 |
| Fullday Change Percent | 6.666669 |
| Fullday Price | 8.8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.87958 |
| Gross Profits | 73,337,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.19805 |
| Held Percent Institutions | 0.52452 |
| Implied Shares Outstanding | 55,087,990 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-07-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California. |
| Long Name | Sight Sciences, Inc. |
| Market | us_market |
| Market Cap | 484,774,336 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_141058155 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -29,757,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 468,798,794 |
| Number Of Analyst Opinions | 5 |
| Open | 8.53 |
| Operating Cashflow | -23,238,000 |
| Operating Margins | -0.16624 |
| Overall Risk | 6 |
| Phone | 877 266 1144 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.8 |
| Post Market Time | 1,792,096,859 |
| Previous Close | 8.25 |
| Price Eps Current Year | -17.862944 |
| Price Hint | 2 |
| Price To Book | 9.10031 |
| Price To Sales Trailing12 Months | 5.814245 |
| Profit Margins | -0.35689998 |
| Quick Ratio | 4.446 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.71429 |
| Region | US |
| Regular Market Change | 0.55 |
| Regular Market Change Percent | 6.66667 |
| Regular Market Day High | 9.01 |
| Regular Market Day Low | 8.53 |
| Regular Market Day Range | 8.53 - 9.01 |
| Regular Market Open | 8.53 |
| Regular Market Previous Close | 8.25 |
| Regular Market Price | 8.8 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 282,037 |
| Return On Assets | -0.10840999 |
| Return On Equity | -0.48422 |
| Revenue Growth | 0.195 |
| Revenue Per Share | 1.559 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 55,087,990 |
| Shares Percent Shares Out | 0.0257 |
| Shares Short | 1,416,320 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,223,511 |
| Short Name | Sight Sciences, Inc. |
| Short Percent Of Float | 0.0353 |
| Short Ratio | 5.66 |
| Source Interval | 15 |
| State | CA |
| Symbol | SGHT |
| Target High Price | 12.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 9.4 |
| Target Median Price | 9.0 |
| Total Cash | 79,753,000 |
| Total Cash Per Share | 1.448 |
| Total Debt | 41,974,000 |
| Total Revenue | 83,377,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.90305 |
| Two Hundred Day Average Change | 2.8969502 |
| Two Hundred Day Average Change Percent | 0.4907548 |
| Type Disp | Equity |
| Volume | 282,037 |
| Website | https://www.sightsciences.com |
| Zip | 94,025 |